Trials / Completed
CompletedNCT00567723
Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)
A Phase-IV, Long-term, Observational Safety Study in End Stage Renal Disease Subjects Treated With Lanthanum Carbonate (Fosrenol)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,105 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients who have been treated with Fosrenol for a minimum of 12 consecutive weeks and are receiving dialysis will be followed for 5 years to compare mortality, bone fractures and incidence of selected morbidities to patients with no lanthanum exposure and to patients being treated for hyperphosphatemia with any marketed product.
Conditions
Timeline
- Start date
- 2006-04-25
- Primary completion
- 2016-06-07
- Completion
- 2016-06-07
- First posted
- 2007-12-05
- Last updated
- 2021-03-17
Locations
199 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00567723. Inclusion in this directory is not an endorsement.